Physician profile
Rahil Shah
NPI 1235172651
$10,019.53
in general payments reported to CMS, 2019-2025
31 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,503 · 2020: $894 · 2021: $879 · 2022: $1,344 · 2023: $1,815 · 2024: $2,501 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,399.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,624.23 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,352.61 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,084.25 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $756.47 | 2022-2024 | Zeposia |
| Janssen Biotech, INC. | $457.78 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Pfizer INC. | $423.06 | 2019-2025 | |
| Qol Medical, LLC | $404.66 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $403.75 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $371.84 | 2019-2024 | |
| Intercept Pharmaceuticals, INC. | $313.71 | 2020-2025 | Ocaliva |
| Ardelyx, INC. | $203.79 | 2022-2025 | Ibsrela |
| Neurocrine Biosciences, INC. | $170.51 | 2024-2025 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $164.00 | 2023-2025 | Voquezna |
| Allergan, INC. | $132.96 | 2019-2020 | |
| Redhill Biopharma INC. | $129.04 | 2020-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $115.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $115.42 | 2024-2025 | Zenpep, Vowst |
| Evoke Pharma, INC. | $113.37 | 2020-2025 | Gimoti |
| Fujifilm Healthcare Americas Corporation | $96.64 | 2023 | Utaswako Afp-L3 |
| Merck Sharp & Dohme LLC | $94.45 | 2019-2022 | |
| Genzyme Corporation | $76.12 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $69.13 | 2024-2025 | Dupixent |
| Braintree Laboratories, INC. | $62.50 | 2019-2022 | |
| Concordia Pharmaceuticals INC. | $62.02 | 2019 | |
| Ferring Pharmaceuticals INC. | $55.27 | 2021-2023 | Rebyota |
| Shionogi INC | $47.56 | 2019 | |
| Medtronic, INC. | $35.79 | 2023 | Gi Genius |
| Lilly USA, LLC | $35.06 | 2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $19.68 | 2025 | Iqirvo |
| Capsovision, INC. | $15.46 | 2023 | Capsocam Plus |
| Exact Sciences Corporation | $12.83 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahil Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.